Published on 3/31/2015 in the Prospect News PIPE Daily.
Cellceutix to conduct $30 million common stock purchase agreement
Investor Aspire Capital commits to buy company shares over three years
By Devika Patel
Knoxville, Tenn., March 31 – Cellceutix Corp. arranged a $30 million three-year common stock purchase agreement with Aspire Capital Fund, LLC on March 30, according to an 8-K filed Monday with the Securities and Exchange Commission.
The biopharmaceutical company is based in Beverly, Mass.
| Issuer: | Cellceutix Corp.
|
| Issue: | Common stock purchase agreement
|
| Amount: | $30 million
|
| Tenor: | Three years
|
| Warrants: | No
|
| Investor: | Aspire Capital Fund, LLC
|
| Settlement date: | March 30
|
| Stock symbol: | OTCBB: CTIX
|
| Stock price: | $3.11 at close March 27
|
| Market capitalization: | $368.58 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
